Company: PHAT
Filing Date: 2025-03-06
Form Type: 10-K
Source: 0000950170-25-034183
Chunk: 351

Company: Phathom Pharmaceuticals, Inc.
Filing Date: 2025-03-06
Form: 10-K
Item: Item 8
Chunk 351
---
 $
    378,318

    $
    413,842

    Liabilities and Stockholders’ Deficit

    Current liabilities:

    Accounts payable
     
    $
    10,507

    $
    12,601

    Accrued expenses

    53,232

    17,197

    Accrued interest

    1,711

    1,146

    Operating lease liabilities, current

    501

    726

    Current portion of revenue interest financing liability

    19,777

    7,111

    Total current liabilities

    85,728

    38,781

    Long-term debt, net of discount

    201,409

    137,842

    Revenue interest financing liability

    333,261

    299,816

    Operating lease liabilities

    —

    462

    Other long-term liabilities

    11,500

    9,700

    Total liabilities

    631,898

    486,601

    Commitments and contingencies (Note 3)

    Stockholders’ deficit:

    Preferred stock, $0.0001 par value; authorized shares — 40,000,000 at December 31, 2024 and December 31, 2023; no shares issued and outstanding at December 31, 2024 and December 31, 2023

    —

    —

    Common stock, $0.0001 par value; authorized shares — 400,000,000 at December 31, 2024 and December 31, 2023; issued and outstanding shares — 68,518,238 and 57,970,044 at December 31, 2024 and December 31, 2023, respectively

    6

    5

    Treasury stock — 19 shares at December 31, 2024 and December 31, 2023

    —

    —

    Additional paid-in capital

    1,009,425

    855,921

    Accumulated deficit

    (1,263,011
    )

    (928,685
    )

    Total stockholders’ deficit

    (253,580
    )

    (72,759
    )

    Total liabilities and stockholders’ deficit
     
    $
    378,318

    $